Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00424840 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy
A Phase 1 study, sponsored by University of Massachusetts, Worcester.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00424840: Clinical Trial Phase 1 study, sponsored by University of Massachusetts, Worcester.
NCT00424840 is a Phase 1 study that was terminated before completion, run by University of Massachusetts, Worcester. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00424840, a Phase 1 study, was terminated before completion, sponsored by University of Massachusetts, Worcester.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
A pilot trial of combination of bortezomib, bevacizumab and carboplatin as first line therapy in patients with metastatic Non-Small Cell Lung Cancer (NSCLC). Phase I and II study of this combination in first line setting will be conducted in order to properly estimate the efficacy and safety of this regimen. This will form the basis for future studies comparing this combination to what is now considered standard regimen for first line therapy in patients with NSCLC, carboplatin, paclitaxel and bevacizumab.
Primary Outcome
Dose limiting toxicity at Level 1,2 and 3: Number of subjects who required dose delay/reduction in dose of bortezomib in the first cycle of treatment. DLT defined by any of the following during first cycle: (1) GR4 neutropenia or thrombocytopenia, (2) Greater than GR3 non-hematological toxicity except alopecia or inadequately treated nausea or vomiting or (3) neurosensory toxicity of GR2 with pain or any neurotoxicity greater than GR2.
Interventions
- DRUG Bevacizumab
- DRUG Carboplatin AUC 6
- DRUG Bortezomib 1.3 mg/m2
- DRUG Bortezomib 1.6 mg/m2
- DRUG Bortezomib 1.8 mg/m2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2006-06 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Why NCT00424840 stopped before completion
NCT00424840 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT00424840 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00424840 about?
NCT00424840 is a clinical study titled "Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy". A pilot trial of combination of bortezomib, bevacizumab and carboplatin as first line therapy in patients with metastatic Non-Small Cell Lung Cancer (NSCLC). Phase I and II study of this combination in first line setting will be conducted in order to properly estimate the efficacy and safety of this...
What is the current status of trial NCT00424840?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2006-06. Estimated completion is 2014-03.
What interventions are being tested in trial NCT00424840?
The interventions under investigation include: Bevacizumab (DRUG), Carboplatin AUC 6 (DRUG), Bortezomib 1.3 mg/m2 (DRUG), Bortezomib 1.6 mg/m2 (DRUG), Bortezomib 1.8 mg/m2 (DRUG).
Who is sponsoring clinical trial NCT00424840?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00424840's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia